SEC Form 4 · accession 0000907654-26-000097
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arjun Agarwal
Officer — Senior Vice President, Finance
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 7:17 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 11, 2026 | M | 8,000 | $12.50 | A | 23,312 | D | |
| Common Stock | Sep 11, 2026 | M | 1,459 | $34.39 | A | 24,771 | D | |
| Common StockF2 | Sep 11, 2026 | S | 3,000 | $91.1073 | D | 21,771 | D | |
| Common StockF3 | Sep 11, 2026 | S | 4,051 | $92.4135 | D | 17,720 | D | |
| Common StockF4 | Sep 11, 2026 | S | 2,208 | $93.2611 | D | 15,512 | D | |
| Common StockF5 | Sep 11, 2026 | S | 200 | $94.015 | D | 15,312 | D | |
| Common Stock | Sep 15, 2026 | S | 560 | $95.71 | D | 14,752 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F7 | $12.50 | Sep 11, 2026 | M | 8,000 | D | — | Jan 21, 2035 | Common Stock | 8,000 | 84,917 | D |
| Employee Stock Option (right to buy)F8 | $34.39 | Sep 11, 2026 | M | 1,459 | D | — | Jan 22, 2036 | Common Stock | 1,459 | 58,333 | D |
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.71 to $91.50, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.74 to $92.71, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.775 to $93.40, inclusive.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.98 to $94.05, inclusive.
- F6The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
- F7The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
- F8The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.